Form 8-K - Current report:
SEC Accession No. 0001683168-25-005392
Filing Date
2025-07-25
Accepted
2025-07-25 13:36:29
Documents
16
Period of Report
2025-07-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT phio_8k.htm   iXBRL 8-K 28059
2 PRESS RELEASE phio_ex9901.htm EX-99.1 11327
3 PRESS RELEASE phio_ex9902.htm EX-99.2 12778
7 GRAPHIC image_001.jpg GRAPHIC 2282
8 GRAPHIC image_002.jpg GRAPHIC 2282
  Complete submission text file 0001683168-25-005392.txt   232763

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE phio-20250725.xsd EX-101.SCH 3020
5 XBRL LABEL FILE phio-20250725_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE phio-20250725_pre.xml EX-101.PRE 22362
18 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3729
Mailing Address 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA 19406
Business Address 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA 19406 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 453215903 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 251150979
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)